MENLO PARK, Calif.--(BUSINESS WIRE)--SRI International, an independent nonprofit research and development organization, today announced that SRI has received support through the Rapid Access to Intervention Development (RAID) program of the National Cancer Institute (NCI). Approved applications to RAID gain access to the drug development resources of the Developmental Therapeutics Program. These resources will be used to further the preclinical development of SRI’s drug SR16388 to treat advanced cancers. This novel antiangiogenic drug is currently in development for the treatment of multiple tumor types including metastatic prostate cancer
